Latest TroVax Stories
WORCESTER, Mass. and TORONTO, June 7, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc. The meeting has been scheduled for June 18, 2012 with FDA regulatory management staff in the Office of...
Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA® Plus Prednisone TORONTO, June 2, 2012 /CNW/ - New data presented this weekend at the 48(th) annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA® (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy....
SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago. Oncothyreon also provided an update on the status of its ongoing Phase 2 development program for PX-866. Phase 1 Trial of PX-866 in Combination with Docetaxel Data from the Phase 1 portion of...
SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final...
TUEBINGEN, Germany, May 25, 2012 /PRNewswire/ -- immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards recognize entrepreneurship, innovation and...
WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL. An abstract entitled "From bench to bedside: The use of the li-Key...
Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4. "This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer...
HOUSTON, March 8, 2012 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe(TM) and DeCIDe(TM) programs through Phase 2 clinical development. The additional funding strengthens Bellicum's balance sheet with $26 million of committed capital, including a $6.1 million award from the Cancer Prevention and Research Institute of Texas (CPRIT). Current and new investors...
DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG(TM), the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer...
TUEBINGEN, Germany, January 24, 2012 /PRNewswire/ -- Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile immatics' unique XPRESIDENT(TM) platform delivers a second promising therapeutic cancer vaccine candidate immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive...
